1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-19 am EDT
323.35 CHF   +1.06%
08/18Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
CI
08/17FDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
AQ
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases

06/17/2022 | 09:52am EDT

Denmark - Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up.

Nordic Bioscience is a world leader in Extracellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

Under the collaboration, Nordic Bioscience will transfer unique and proprietary blood-based biomarkers to Roche Diagnostics to be implemented on the automated COBAS platform. Nordic Bioscience's ECM biomarkers are unique and essential for all chronic diseases involving tissue fibrosis and inflammation. The collaboration will facilitate better clinical decisions in drug development and patient selection as well as enrichment for precision medicine and ultimately improve patient outcomes.

Nordic Biosciences has a long and successful collaboration with Roche Diagnostics. To date, two biomarkers have been commercialized and implemented on the Roche automated COBAS platform. Nordic Bioscience's fibrogenesis biomarker PRO-C3 has become a commonly used next-generation and noninvasive biomarker to quantify type III collagen formation which is highly relevant for NASH and other fibrotic diseases.

PRO-C6 quantifies type VI collagen formation, which is highly relevant for cardiovascular diseases and various cancer types. The FDA recently published a letter of support for further studies of PRO-C6 as a trial enrichment and patient selection biomarker in relation to Heart Failure with Preserved Ejection Fraction (HFpEF).

PRO-C3 and PRO-C6 are part of Nordic Bioscience's portfolio of ECM biomarkers which are being developed and commercialized both as research tools and in the future as diagnostic products. Both biomarkers have completed the technical development from manual ELISA to automated version on the COBAS platform. They are validated and currently running in routine in the CAP-accredited laboratory of Nordic Bioscience.

'The collaboration with Roche Diagnostics is an important step for Nordic Bioscience in our efforts to help accelerate drug development. Having our biomarkers on the Roche Diagnostics' platform and our combined capabilities will secure global availability of our best ECM biomarkers. This also adds significant value to Nordic Bioscience offerings as we transform our biomarkers from tools used only in clinical development to globally available diagnostics products', said Morten Karsdal Chief Executive Officer of Nordic Bioscience.

Nordic Bioscience has a long track record of research in ECM remodeling, which previously has resulted in the transfer of the FDA-approved bone biomarker CTX-I to the Roche COBAS platform. Nordic Bioscience has developed more than 125 ELISA biomarkers focusing on quantifying unique fragments of the ECM. These tools are used in all phases of drug development and for patient selection in various diseases.

Contact:

Hollie Vile

Tel: +44 (0) 203 922 0891

Email: nordicbio@optimumcomms.com

About Nordic Bioscience

Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about ROCHE HOLDING AG
08/18Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercia..
CI
08/17FDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
AQ
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
08/16Genentech - FDA Accepts Supplemental Biologics License Application for Genentech's Poli..
AQ
08/16Swiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
08/16FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combinati..
BU
08/16FDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
GL
08/16U.S. Food and Drug Administration Accepts Supplemental Biologics License Application by..
CI
08/15Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
RE
08/15Roche Unveils New Diagnostic Test for COVID-19 Immune Response
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 249 M 67 003 M 67 003 M
Net income 2022 14 824 M 15 460 M 15 460 M
Net Debt 2022 10 272 M 10 712 M 10 712 M
P/E ratio 2022 17,3x
Yield 2022 2,99%
Capitalization 266 B 277 B 277 B
EV / Sales 2022 4,29x
EV / Sales 2023 4,17x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 323,35 CHF
Average target price 374,13 CHF
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-15.60%276 954
JOHNSON & JOHNSON-1.03%438 468
ELI LILLY AND COMPANY14.66%300 939
PFIZER, INC.-16.77%272 648
ABBVIE INC.4.35%249 814
NOVO NORDISK A/S2.97%233 688